%0 Journal Article
%A Svačina, Martin K. R.
%A Sprenger-Svačina, Alina
%A Tsakmaklis, Anastasia
%A Rüb, Alina M.
%A Klein, Ines
%A Wüstenberg, Hauke
%A Fink, Gereon R.
%A Lehmann, Helmar C.
%A Vehreschild, Maria J. G. T.
%A Farowski, Fedja
%T The gut microbiome in intravenous immunoglobulin‐treated chronic inflammatory demyelinating polyneuropathy
%J European journal of neurology
%V 30
%N 11
%@ 1351-5101
%C Oxford [u.a.]
%I Wiley-Blackwell
%M FZJ-2023-01611
%P 3551-3556
%D 2023
%X AbstractBackground and purpose: The gut microbiome is involved in autoimmunity. Data on its composition in chronic inflammatory demyelinating polyneuropathy (CIDP), the most common chronic autoimmune disorder of peripheral nerves, are currently lacking.Methods: In this monocentric exploratory pilot study, stool samples were prospectively collected from 16 CIDP patients (mean age 58 ± 10 years, 25% female) before and 1 week after administration of intravenous immunoglobulin (IVIg). Gut microbiota were analyzed via bacterial 16S rRNA gene sequencing and compared to 15 age-matched healthy subjects (mean age 59 ± 15 years, 66% female).Results: The gut microbiota of CIDP patients showed an increased alpha-diversity (p = 0.005) and enrichment of Firmicutes, such as Blautia (p = 0.0004), Eubacterium hallii (p = 0.0004), or Ruminococcus torques (p = 0.03), and of Actinobacteriota (p = 0.03) compared to healthy subjects. IVIg administration did not alter the gut microbiome composition in CIDP in this short-term observation (p = 0.95).Conclusions: The gut microbiome in IVIg-treated CIDP shows distinct features, with increased bacterial diversity and enrichment of short-chain fatty acid producing Firmicutes. IVIg had no short-term impact on the gut microbiome in CIDP patients. As the main limitation of this exploratory pilot study was small cohort size, future studies also including therapy-naïve patients are warranted to verify our findings and to explore the impact of long-term IVIg treatment on the gut microbiome in CIDP.Keywords: autoimmunity; firmicutes; immune neuropathies; intestinal barrier; short-chain fatty acids (SCFA).
%F PUB:(DE-HGF)16
%9 Journal Article
%$ 36651357
%U <Go to ISI:>//WOS:000925036100001
%R 10.1111/ene.15679
%U https://juser.fz-juelich.de/record/1005757